331 related articles for article (PubMed ID: 20577046)
1. An energetic tale of AMPK-independent effects of metformin.
Miller RA; Birnbaum MJ
J Clin Invest; 2010 Jul; 120(7):2267-70. PubMed ID: 20577046
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
Foretz M; Hébrard S; Leclerc J; Zarrinpashneh E; Soty M; Mithieux G; Sakamoto K; Andreelli F; Viollet B
J Clin Invest; 2010 Jul; 120(7):2355-69. PubMed ID: 20577053
[TBL] [Abstract][Full Text] [Related]
3. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.
Miller RA; Chu Q; Xie J; Foretz M; Viollet B; Birnbaum MJ
Nature; 2013 Feb; 494(7436):256-60. PubMed ID: 23292513
[TBL] [Abstract][Full Text] [Related]
4. Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
Aw DK; Sinha RA; Xie SY; Yen PM
Biochem Biophys Res Commun; 2014 May; 447(4):569-73. PubMed ID: 24735537
[TBL] [Abstract][Full Text] [Related]
5. Role of AMP-activated protein kinase in mechanism of metformin action.
Zhou G; Myers R; Li Y; Chen Y; Shen X; Fenyk-Melody J; Wu M; Ventre J; Doebber T; Fujii N; Musi N; Hirshman MF; Goodyear LJ; Moller DE
J Clin Invest; 2001 Oct; 108(8):1167-74. PubMed ID: 11602624
[TBL] [Abstract][Full Text] [Related]
6. Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.
Wang Y; An H; Liu T; Qin C; Sesaki H; Guo S; Radovick S; Hussain M; Maheshwari A; Wondisford FE; O'Rourke B; He L
Cell Rep; 2019 Nov; 29(6):1511-1523.e5. PubMed ID: 31693892
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the mechanisms of metformin action in the liver.
Viollet B; Foretz M
Ann Endocrinol (Paris); 2013 May; 74(2):123-9. PubMed ID: 23582849
[TBL] [Abstract][Full Text] [Related]
8. Metformin Activates AMPK through the Lysosomal Pathway.
Zhang CS; Li M; Ma T; Zong Y; Cui J; Feng JW; Wu YQ; Lin SY; Lin SC
Cell Metab; 2016 Oct; 24(4):521-522. PubMed ID: 27732831
[No Abstract] [Full Text] [Related]
9. AMP-activated protein kinase in metabolic control and insulin signaling.
Towler MC; Hardie DG
Circ Res; 2007 Feb; 100(3):328-41. PubMed ID: 17307971
[TBL] [Abstract][Full Text] [Related]
10. The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production.
An H; Wang Y; Qin C; Li M; Maheshwari A; He L
Sci Rep; 2020 Jun; 10(1):10482. PubMed ID: 32591547
[TBL] [Abstract][Full Text] [Related]
11. AMPK-SIRT1-independent inhibition of ANGPTL3 gene expression is a potential lipid-lowering mechanism of metformin.
Lin L; Burke J; Venkatesh S; Sadana P
J Pharm Pharmacol; 2019 Sep; 71(9):1421-1428. PubMed ID: 31273790
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice.
Rada P; Mosquera A; Muntané J; Ferrandiz F; Rodriguez-Mañas L; de Pablo F; González-Canudas J; Valverde ÁM
Food Chem Toxicol; 2019 Jan; 123():470-480. PubMed ID: 30414960
[TBL] [Abstract][Full Text] [Related]
13. Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action.
Takashima M; Ogawa W; Hayashi K; Inoue H; Kinoshita S; Okamoto Y; Sakaue H; Wataoka Y; Emi A; Senga Y; Matsuki Y; Watanabe E; Hiramatsu R; Kasuga M
Diabetes; 2010 Jul; 59(7):1608-15. PubMed ID: 20393151
[TBL] [Abstract][Full Text] [Related]
14. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.
Zang M; Zuccollo A; Hou X; Nagata D; Walsh K; Herscovitz H; Brecher P; Ruderman NB; Cohen RA
J Biol Chem; 2004 Nov; 279(46):47898-905. PubMed ID: 15371448
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.
Kim YD; Park KG; Lee YS; Park YY; Kim DK; Nedumaran B; Jang WG; Cho WJ; Ha J; Lee IK; Lee CH; Choi HS
Diabetes; 2008 Feb; 57(2):306-14. PubMed ID: 17909097
[TBL] [Abstract][Full Text] [Related]
16. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).
Cao J; Meng S; Chang E; Beckwith-Fickas K; Xiong L; Cole RN; Radovick S; Wondisford FE; He L
J Biol Chem; 2014 Jul; 289(30):20435-46. PubMed ID: 24928508
[TBL] [Abstract][Full Text] [Related]
17. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.
Ford RJ; Fullerton MD; Pinkosky SL; Day EA; Scott JW; Oakhill JS; Bujak AL; Smith BK; Crane JD; Blümer RM; Marcinko K; Kemp BE; Gerstein HC; Steinberg GR
Biochem J; 2015 May; 468(1):125-32. PubMed ID: 25742316
[TBL] [Abstract][Full Text] [Related]
18. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Foretz M; Guigas B; Viollet B
Nat Rev Endocrinol; 2019 Oct; 15(10):569-589. PubMed ID: 31439934
[TBL] [Abstract][Full Text] [Related]
19. Metformin--mode of action and clinical implications for diabetes and cancer.
Pernicova I; Korbonits M
Nat Rev Endocrinol; 2014 Mar; 10(3):143-56. PubMed ID: 24393785
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic variation and metformin response.
Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
